β-Glucuronidase triggers extracellular MMAE release from an integrin-targeted conjugate
- 22 April 2019
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 17 (19) , 4705-4710
Abstract
A non-internalizing conjugate targeting αvβ3 integrin inhibits the proliferation of integrin-expressing cancer cells in the presence of β-glucuronidase.Keywords
Funding Information
- European Commission (Marie Skłodowska-Curie ITN MAGICBULLET 642004)
- Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN 2015 20157WW5EH)
This publication has 49 references indexed in Scilit:
- Selective Cancer Therapy by Extracellular Activation of a Highly Potent Glycosidic Duocarmycin AnalogueMolecular Pharmaceutics, 2013
- Small Targeted Cytotoxics: Current State and Promises from DNA‐Encoded Chemical LibrariesAngewandte Chemie International Edition, 2013
- Synthesis and Biological Evaluation (in Vitro and in Vivo) of Cyclic Arginine–Glycine–Aspartate (RGD) Peptidomimetic–Paclitaxel Conjugates Targeting Integrin αVβ3Journal of Medicinal Chemistry, 2012
- Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progressJournal of Controlled Release, 2012
- Direct Fluorescence Monitoring of the Delivery and Cellular Uptake of a Cancer-Targeted RGD Peptide-Appended Naphthalimide Theragnostic ProdrugJournal of the American Chemical Society, 2012
- A Traceless Vascular‐Targeting Antibody–Drug Conjugate for Cancer TherapyAngewandte Chemie International Edition, 2011
- Enzyme-mediated hydrolytic activation of prodrugsActa Pharmaceutica Sinica B, 2011
- Cancer-Stroma Targeting Therapy by Cytotoxic Immunoconjugate Bound to the Collagen 4 Network in the Tumor TissueBioconjugate Chemistry, 2011
- Integrins in cancer: biological implications and therapeutic opportunitiesNature Reviews Cancer, 2010
- Development and Properties of β-Glucuronide Linkers for Monoclonal Antibody−Drug ConjugatesBioconjugate Chemistry, 2006